openPR Logo
Press release

BACE Inhibitors Exhibit an Emerging Pipeline with 10+ Drug Candidates

03-17-2017 11:18 AM CET | Health & Medicine

Press release from: P&S Market Research- Pharmaceuticals

BACE Inhibitors Exhibit an Emerging Pipeline with 10+ Drug

BACE inhibitors offer novel therapeutic approach for the treatment of Alzheimer’s disease

The study analyzed that the Beta Secretase inhibitors pipeline comprised 15 drug candidates, of which three products are in Phase III, three products in Phase II, one product in Phase I, and one product is in Discovery. The development of two BACE inhibitor candidates was found to be inactive, and five products were discontinued. BACE is a cleaving enzyme of aspartyl protease with beta-secretase activity. It acts as a precursor of beta-amyloid (Aβ) protein. In Alzheimer’s disease, the Aβ protein fragments get accumulated in plaques in the brain. BACE initiates Aβ production by cleaving amyloid precursor protein (APP) to generate APPβ and C99, which is critical for the subsequent cleavage of C99 by gamma-secretase to release Aβ1-40 and Aβ1-42. Inhibition of BACE enzyme disrupts the production of toxic Aβ and formed plaque and new soluble oligomers.

Browse the Report Summary at: www.psmarketresearch.com/market-analysis/beta-secretase-inhibitors-pipeline-analysis

Insights on pipeline segments

As per the findings of the research, around 80% pipeline drug candidates of BACE inhibitors are being developed to be administered by oral route and 7% by intravenous route. Most of the therapeutic candidates are being developed to be administered by oral route due to high patient compliance.

Alzheimer’s disease drug development receives Fast Track designation

Among BACE inhibitors, AZD3293, a drug candidate of AstraZeneca plc and Eli Lilly and Company, received Fast Track designation by the U.S. Food and Drug Administration (FDA) in August 2016. The FDA’s Fast Track program was designed to expedite the development and review new therapies to treat serious conditions and tackle unmet medical needs.

Browse Report Sample at: www.psmarketresearch.com/market-analysis/beta-secretase-inhibitors-pipeline-analysis/report-sample

Major companies collaborate for the development of BACE inhibitors

The research finds that different companies collaborated for the development of BACE inhibitors. In September 2015, Novartis entered in a global collaboration with Amgen to commercialize and develop BACE inhibitor program in Alzheimer's disease. Novartis oral CNP520 will be the lead molecule and further compounds from both companies’ Pre-Clinical BACE inhibitor programs may be considered as follow-on molecules. The collaboration also focused on new Amgen drugs in the migraine field, including Phase III AMG 334 and Phase I AMG 301. For the migraine program, Novartis was expected to have global co-development rights and commercial rights outside the U.S., Canada and Japan.

Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals

Some of the key players developing BACE inhibitors are AstraZeneca plc, Eli Lilly & Company, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Eisai & Co., Ltd., CoMentis, Inc., vTv Therapeutics, Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., and Boehringer Ingelheim GmbH.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-Free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: www.psmarketresearch.com

347, 5th Ave. #1402
New York City, NY - 10016

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release BACE Inhibitors Exhibit an Emerging Pipeline with 10+ Drug Candidates here

News-ID: 472155 • Views:

More Releases from P&S Market Research- Pharmaceuticals

Benign Prostatic Hyperplasia Therapeutics Market - Epidemiology Analysis, Therapy, Development, Growth and Demand Forecast to 2023
Benign Prostatic Hyperplasia Therapeutics Market - Epidemiology Analysis, Therap …
The global benign prostatic hyperplasia therapeutics market is expected to witness significant growth, as increased number of effective treatments are available for cancer. Increasing awareness regarding various cancer treatment drugs, technological advancements, and growing demand for safe and effective medications are acting as the major growth drivers for the benign prostatic hyperplasia therapeutics market. Globally, regulatory bodies are adding to the growth of the market with provision of funding, grants
Global Esophageal Cancer Therapeutics Market Analysis, Development and Demand Forecast to 2023
Global Esophageal Cancer Therapeutics Market Analysis, Development and Demand Fo …
Global esophageal cancer therapeutics market is expected to witness significant growth with an increasing awareness regarding cancer treatment and technological advancements. Also, high demand for safe and effective medications and rising prevalence of cancer are driving the growth of the global market. The regulatory bodies such as USFDA, EMA are supporting the growth of the global market by providing funding, designations and grants for speeding up the drug development process. Explore
Pancreatic Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Development and Demand Forecast to 2023
Pancreatic Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Developm …
The global pancreatic cancer therapeutics market holds numerous opportunities for the key players, as pancreatic cancer is a highly challenging disease among all types of cancer, which has no specific treatment available for it, as of now. Also, growing incidence of cancer and technological advancements are supporting the growth of the global pancreatic cancer therapeutics market growth. Explore Report at: www.psmarketresearch.com/market-analysis/pancreatic-cancer-therapeutics-market Cancer instigates uncountable growth of cells due to some abnormalities
Novel Targets for Breast Cancer Treatment Drive Estrogen Receptor-Positive (ER+) Breast Cancer Pipeline Growth
Novel Targets for Breast Cancer Treatment Drive Estrogen Receptor-Positive (ER+) …
Estrogen Receptor-Positive (ER+) breast cancer currently exhibits a pipeline with 46 active drug candidates. ER+ breast cancer pipeline offers novel therapeutic targets for the treatment of breast cancer The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates, of which nine products are in Phase III, 16 products in Phase II, 18 products in Phase I, and three products are in Pre-Clinical stage. The development of

All 5 Releases


More Releases for BACE

Recycling Compactors Market Size, Growth and SWOT Analysis by Key Players: BACE, …
The report offers in-depth analysis of the global Recycling Compactor market taking into account market dynamics, segmentation, geographical expansion, competitive landscape, and various other key aspects. The market analysts who have prepared the report have thoroughly studied the global Recycling Compactor market and have offered reliable and accurate data. They understand the needs of the industry and the clients, which makes it easy for them to focus on the aspects,
Pharma News: BACE Inhibitors Pipeline Analysis - AstraZeneca, Eli Lilly and Comp …
The study analysed that the Beta Secretase inhibitors pipeline comprised 15 drug candidates, in different stages of development. Browse report sample at: https://www.psmarketresearch.com/market-analysis/beta-secretase-inhibitors-pipeline-analysis/report-sample Insights on pipeline segments As per the findings of the research, most of the pipeline drug candidates of BACE inhibitors are being developed to be administered by oral route. Alzheimer’s disease drug development receives Fast Track designation Among BACE inhibitors, AZD3293, a drug candidate of AstraZeneca plc and Eli Lilly and Company,
2019-2025 Rising demands of Global Clay Pipe Market Trends Major Key Companies M …
UpMarketResearch offers a latest published report on “Global Clay Pipe Market Analysis and Forecast 2019-2025” delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 115 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. Get Exclusive FREE Sample Copy Of this Report @ https://www.upmarketresearch.com/home/requested_sample/46566 Clay Pipe Market research report delivers a close watch
Beta-Secretase Inhibitors Pipeline - Key Players Analysis Eli Lilly and Company, …
The study analysed that the Beta Secretase inhibitors pipeline comprised 15 drug candidates, in different stages of development. Browse report sample at: https://www.psmarketresearch.com/market-analysis/beta-secretase-inhibitors-pipeline-analysis/report-sample *Insights on pipeline segments As per the findings of the research, most of the pipeline drug candidates of BACE inhibitors are being developed to be administered by oral route. *Alzheimer’s disease drug development receives Fast Track designation Among BACE inhibitors, AZD3293, a drug candidate of AstraZeneca plc and Eli Lilly and Company,
BACE Inhibitors Pipeline to Witness Huge R&D Investment in the Coming Years
The study analysed that the Beta Secretase inhibitors pipeline comprised 15 drug candidates, in different stages of development. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/beta-secretase-inhibitors-pipeline-analysis As per the findings of the research, most of the pipeline drug candidates of BACE inhibitors are being developed to be administered by oral route. Among BACE inhibitors, AZD3293, a drug candidate of AstraZeneca plc and Eli Lilly and Company, received Fast Track designation by the U.S. Food and
Eastern India to witness the latest of innovations in the engineering and constr …
To be hosted by IPFonline Ltd, ENGEETECH and BACE are two expositions (18th November, 2010 to 21st November, 2010 at the Science City grounds, Kolkata) which will cater to Eastern India’s growing requirement of advanced technology in engineering and construction segment to accelerate infrastructure growth The twin expositions will see manufacturers from 32 Indian cities exhibiting various unique products for the engineering and industrial equipment sectors IPFonline Limited (IPF), one of